From the patients’ perspective, professionals positively present SMBG as a ‘friend’ in order to achieve strict glycemic control. Whereas patients can also perceive SMBG as a ‘foe’ (BMC Public Health)
Variation of Fasting Plasma Glucose: A Predictor of Mortality in Patients with Type 2 Diabetes
Time-dependent variation of FPG was a strong predictor of all-cause, expanded, and nonexpanded cardiovascular disease-related mortality in patients with type 2 diabetes, suggesting that glucose variation may become a measure in clinical practice for the goal in the management of these patients (American Journal of Medicine)
Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes
In obese patients with uncontrolled type 2 diabetes, 12 months of medical therapy plus bariatric surgery achieved glycemic control in significantly more patients than medical therapy alone. Further study will be necessary to assess the durability of these results (New England Journal of Medicine)
Remission of Insulin Resistance in Type 2 Diabetic Patients After Gastric Bypass Surgery or Exenatide Therapy
Gastric bypass surgery is better in weight control and in the remission of insulin resistance compared with exenatide therapy (Obesity Surgery)
Early Neurodegeneration in the Retina of Type 2 Diabetic Patients
This study demonstrates thinner inner retinal layers in the macula of type 2 diabetic patients with minimal DR than in controls. These results support the concept that early DR includes a neurodegenerative component (Investigative Ophthalmology & Visual Science)
Effect of Diabetes Mellitus on Severity and Hospital Mortality in Patients With Acute Pancreatitis
Although diabetes may adversely affect the disease process of AP, it seems to protect patients from AP-related mortality (Diabetes Care)
BYETTA® Approved for Use with Basal Insulin in Europe
Amylin Pharmaceuticals and Eli Lilly and Company announced that the European Commission has granted marketing authorization to BYETTA® (exenatide twice-daily) as an adjunctive therapy to basal insulin, with or without metformin and/or Actos® (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents (Lilly)
Effects of Dapagliflozin, a Sodium-Glucose Cotransporter-2 Inhibitor, on Hemoglobin A1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
In patients with type 2 diabetes inadequately controlled on pioglitazone, the addition of dapagliflozin further reduced HbA1c levels and mitigated the pioglitazone-related weight gain without increasing hypoglycemia risk (Diabetes Care)
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
In treatment-naïve patients with T2D, dapagliflozin plus metformin was generally well tolerated and effective in reducing HbA1c, FPG and weight. Dapagliflozin-induced glucosuria led to an increase in events suggestive of urinary tract and genital infections (International Journal of Clinical Practice)
Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study
Bezafibrate significantly improved HbA1c in patients with diabetes given individualized treatment. Bezafibrate may offer clinicians an improved modality for the amelioration of disease course and improvement of outcome in these patients (Cardiovascular Diabetology)
QiC Programme Diabetes
Entries are invited from anyone working in the diabetes arena. Whatever the area of patient care, if your initiative or programme relates to diabetes in any way, you should enter it. Each initiative will be reviewed by a panel of high-level diabetes experts, chaired by Anna Morton, director, NHS Diabetes, and Simon O’Neill, director of care, information and advocacy at Diabetes UK (QiC)
Join Us On Our Journey
NHS Diabetes commissioned Leeds Metropolitan University to undertake a 3-year research project. The aims of the research were to develop a model of care that will deliver the aspirations of the policy document ‘Making Every Young Person with Diabetes Matter’ and improve the care provision for children and young people with type 1 diabetes in England (NHS)
Glycosmedia is also available as an App: